Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares.


